Scientists identify gene that regulates the growth of melanoma

February 29, 2016 by Ziba Kashef
Microscopic view of malignant melanoma. Credit: Marcus Bosenberg

Yale Cancer Center researchers have identified a gene in melanoma that can dramatically affect the growth of the disease. The findings, published in the journal Cell Reports, provide new insight into how melanoma grows and identifies a new target for treatment of melanoma and other cancers.

Enzymes that chemically modify DNA, known as DNA methyltranferases, play critical roles in regulating gene expression during development, but their role in formation is less clear. The new Yale study has uncovered a novel role for a specific DNA methyltransfearase enzyme—DNMT3B—in regulating melanoma growth.

Abnormally high expression of DNA methyltransferases is common in cancers, including melanoma. High expression of DNA methyltransferases can inappropriately switch genes off or on, which can contribute to tumor formation and growth. However, little is known about the specific growth-signaling pathways affected by DNA methyltransferase enzymes like DNMT3B. Yale researchers identified a specific cell-signaling pathway that is dependent on DNMT3B. They found that reducing DNMT3B delayed melanoma formation in mice by affecting mTORC2, a protein complex that is important for controlling cell growth, size, and survival.

 "We have identified a new target for drug development as well as a new way of targeting an existing pathway. These findings identify DNMT3B as an attractive target for cancer therapy," said Dr. Marcus W. Bosenberg, associate professor of dermatology and pathology at Yale School of Medicine, and senior author on the study.

Malignant melanoma is the most deadly form of skin cancer, accounting for 80% of all skin cancer deaths. The research, published early online by Cell Reports, could lead to development of new strategies to slow growth by targeting DNMT3B, say the researchers.

Explore further: A tiny RNA with a big role in melanoma

More information: Goran Micevic et al. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR, Cell Reports (2016). DOI: 10.1016/j.celrep.2016.02.010

Related Stories

A tiny RNA with a big role in melanoma

February 18, 2014
A Yale-led study has identified a key mechanism in the regulation of gene expression that promotes the proliferation of melanoma cells. The finding opens a possible avenue for development of treatments that target this mechanism. ...

Study identifies 'major player' in skin cancer genes

July 27, 2015
A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important ...

New genetic mutation identified in melanoma cancer cells

September 2, 2015
There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal and breast cancer, and now melanoma. A new study has revealed that a genetic mutation ...

Discovery may lead to targeted melanoma therapies

June 17, 2015
Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published ...

Study finds new potential melanoma drug target

May 2, 2015
A new treatment for melanoma could be on the horizon, thanks to a finding by a UNC Lineberger Comprehensive Cancer Center-led team. In the study, which was published online today in the journal Clinical Cancer Research, the ...

A newly discovered tumor suppressor gene affects melanoma survival

November 2, 2015
Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true "drivers" of cancer. In research that appeared last week in Nature Genetics, a Weizmann Institute of Science team has now ...

Recommended for you

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

Scientists restore tumor-fighting structure to mutated breast cancer proteins

September 20, 2017
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides ...

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

Researchers identify new target, develop new drug for cancer therapies

September 20, 2017
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to ...

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.